FY2026 EPS Estimate for Gossamer Bio Boosted by Analyst

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for Gossamer Bio in a note issued to investors on Friday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($14.09) for the year, up from their prior estimate of ($21.00). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($27.13) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($1.66) EPS, Q2 2027 earnings at ($1.69) EPS, Q3 2027 earnings at ($0.97) EPS, Q4 2027 earnings at ($0.99) EPS, FY2027 earnings at ($5.12) EPS, FY2028 earnings at ($4.15) EPS and FY2029 earnings at ($1.51) EPS.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($7.36) EPS for the quarter, missing the consensus estimate of ($3.79) by ($3.57). The business had revenue of $38.43 million during the quarter, compared to analysts’ expectations of $12.16 million.

GOSS has been the topic of a number of other research reports. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a research report on Tuesday, July 28th. Wedbush decreased their target price on shares of Gossamer Bio to $32.00 and set a “neutral” rating for the company in a research report on Wednesday, November 11th. Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Chardan Capital reissued a “buy” rating on shares of Gossamer Bio in a research report on Monday, October 26th. Finally, Weiss Ratings downgraded shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Gossamer Bio currently has a consensus rating of “Hold” and an average price target of $246.40.

Get Our Latest Stock Analysis on Gossamer Bio

Gossamer Bio Stock Up 0.1%

NASDAQ GOSS opened at $10.98 on Tuesday. Gossamer Bio has a 12-month low of $8.29 and a 12-month high of $309.60. The company has a market capitalization of $67.15 million, a PE ratio of -0.24 and a beta of 2.28. The firm’s 50 day moving average is $10.50 and its 200-day moving average is $31.97.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kalehua Capital Management LLC acquired a new stake in shares of Gossamer Bio in the 1st quarter valued at approximately $3,363,000. GSA Capital Partners LLP acquired a new position in Gossamer Bio during the second quarter worth $2,467,000. ARCH Venture Management LLC bought a new stake in Gossamer Bio during the second quarter worth $1,326,004. BlackRock Inc. bought a new stake in Gossamer Bio during the second quarter worth $1,262,000. Finally, Bank of America Corp DE lifted its stake in Gossamer Bio by 66.5% in the first quarter. Bank of America Corp DE now owns 3,173,725 shares of the company’s stock valued at $1,041,000 after acquiring an additional 1,267,056 shares during the last quarter. Institutional investors own 81.23% of the company’s stock.

Key Headlines Impacting Gossamer Bio

These are some of the GOSS headlines that stood out recently:

  • Positive Sentiment: HC Wainwright improved estimates for FY2026 and FY2027, with FY2026 projected loss narrowing to $14.09 per share from $21.00 and FY2027 to $5.12 from $5.64. It also raised estimates for Q1–Q4 2027, with smaller projected losses, and maintained its “Buy” rating. Gossamer Bio analyst estimates
  • Neutral Sentiment: The analyst’s projections still imply substantial losses, including a $27.13-per-share consensus loss for the current fiscal year; the estimates alone do not indicate a change in Gossamer Bio’s operating outlook. Gossamer Bio financial information
  • Negative Sentiment: Not all revisions were favorable: HC Wainwright widened its projected Q4 2026 loss to $2.02 per share from $1.95, trimmed FY2029 to a $1.51 loss from $1.48, and lowered its FY2030 profit forecast to $2.54 from $2.60. Gossamer Bio FY2030 Earnings Forecast Cut by HC Wainwright

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company develops medicines for serious diseases, with a focus on pulmonary vascular conditions. Its lead candidate is seralutinib, an inhaled investigational therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Seralutinib is not an approved medicine. Gossamer has partnered with Chiesi Group to advance its development.

Recommended Stories

Earnings History and Estimates for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.